Patent Application
20230002460
The content of the electronically submitted sequence listing, file name: Sequence_Listing_As_Filed.txt; size: 218,630 bytes; and date of creation: Apr. 15, 2022, filed herewith, is incorporated herein by reference in its entirety.
The present invention relates to a fusion protein that includes a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition comprising the same.
Growth differentiation factor-15 (GDF15) is also called macrophage inhibitory cytokine-1 (MIC-1), placental bone morphogenetic protein (PBMP), or nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1), and is a protein that is a member of the transforming growth factor-beta (TGF-β) superfamily.
Recently, study results have shown that GDF15 inhibits dietary intake through binding to GDNF family receptor alpha-like (GFRAL) and ret proto-oncogene (RET), which are specifically expressed in brain tissue, and thus results in body weight loss (Tsai V W, et al., PLoS One 2013; 8(2): e55174; U.S. Pat. No. 8,192,735). In addition, several studies have demonstrated that GDF15 has an excellent body weight loss effect in a case of being administered to various obese animal models, and have identified that in addition to such an effect, GDF15 further has metabolic advantages such as lowering blood glucose level, improving lipid level, and improving insulin resistance.
However, the wild-type GDF15 is problematic in that in a case where it is used medically, high frequency of administration is needed due to its short in vivo half-life. Accordingly, efforts are being made to develop long-acting formulations that are intended to increase an in vivo half-life of GDF15.
Meanwhile, among several techniques of producing long-acting formulations, an immunoglobulin Fc fusion technique is most widely used in that it results in increased in vivo half-life and there is little concern about adverse effects such as toxicity or induction of immune responses. To develop an immunoglobulin Fc-fused GDF15 protein into a long-acting therapeutic drug, the following several conditions must be satisfied.
First, decrease in in vitro activity caused by fusion should be minimized. It is known that activity of GDF15 fusion proteins varies greatly depending on fusion site. Therefore, activity of Fc-fused GDF15 proteins, in which a mutation has been introduced into the GDF15, may vary depending on whether fusion has occurred or fusion site. Second, fusion should result in increased in vivo half-life, and the increased in vivo half-life should display a pharmacokinetic profile which enables administration at an interval of once a week in humans. Third, considering that most biopharmaceuticals may cause immunogenicity in patients, risk of immunogenicity caused by a fusion linker or mutation should be minimized. Fourth, there should be no stability problems due to fusion site or mutation introduction. Fifth, since an unwanted immune response may occur depending on isotypes of fused immunoglobulin, an alternative thereto is required.
While making efforts to improve physiological activity and stability of GDF15, the present inventors have identified that in a case where a mutation is introduced at a particular location of GDF15 and an immunoglobulin Fc region is bound thereto, the GDF15 has enhanced activity and increased in vivo half-life, and thus have completed the present invention.
An object of the present invention is to provide a GDF15 variant having improved physiological activity and stability, and a long-acting GDF15 fusion protein.
Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising, as an active ingredient, the GDF15 variant or the long-acting GDF15 fusion protein.
To achieve the above objects, in an aspect of the present invention, there is provided a GDF15 variant represented by Formula (I).
N-terminal extension domain-core domain (I)
In another aspect of the present invention, there is provided a long-acting GDF15 fusion protein, in which the GDF15 variant is bound to human IgG Fc or a variant thereof.
In yet another aspect of the present invention, there is provided a fusion protein dimer, comprising two of the long-acting GDF15 fusion protein.
In still yet another aspect of the present invention, there is provided an isolated nucleic acid molecule, encoding the GDF15 variant or the GDF15 fusion protein.
In still yet another aspect of the present invention, there is provided an expression vector, comprising the nucleic acid molecule.
In still yet another aspect of the present invention, there is provided a host cell, comprising the expression vector.
In still yet another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer.
The GDF15 variant or the long-acting GDF15 fusion protein, according to the present invention, is superior to conventional GDF15 variants in terms of in vitro efficacy, binding affinity for GDF15 receptors, and body weight loss effect.
Therefore, a pharmaceutical composition, which comprises, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, of the present invention, causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity.
Furthermore, the pharmaceutical composition, which comprises, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, can be used in combination therapy or the like with chemical drugs and other therapeutic agents for metabolic diseases, and can be effectively used in combination therapy with conventional therapeutic agents for metabolic diseases or obesity.
Hereinafter, the present invention will be described in more detail.
GDF15 Variant
In an aspect of the present invention, there is provided a GDF15 variant represented by Formula (I):
N-terminal extension domain-core domain (I).
In Formula (I),
the N-terminal extension domain is a polypeptide consisting of any one amino acid sequence of SEQ ID NOs: 3 to 5; and
the core domain is a polypeptide represented by SEQ ID NO: 20, or a polypeptide derived from SEQ ID NO: 20 in which any one amino acid selected from the group consisting of amino acids at positions 15, 50, 58, 97, and combinations thereof in the amino acid sequence of SEQ ID NO: 20 is substituted with another amino acid;
wherein arginine (R), which is the amino acid at position 15, may be substituted with alanine (A), aspartic acid (D), asparagine (N), cysteine (C), glutamic acid (E), glutamine (Q), glycine (G), histidine (H), isoleucine (I), leucine (L), lysine (K), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), or valine (V),
asparagine (N), which is the amino acid at position 50, may be substituted with alanine, arginine (R), aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine,
serine (S), which is the amino acid at position 58, may be substituted with alanine, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, or valine, and
aspartic acid (D), which is the amino acid at position 97, may be substituted with alanine, arginine, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
As used herein, the term “core domain” refers to a polypeptide having an amino acid sequence from positions 7 to 112 in the amino acid sequence of GDF15 of SEQ ID NO: 1, including a polypeptide represented by SEQ ID NO: 20, or a polypeptide derived from SEQ ID NO: 20 in which any one amino acid selected from the group consisting of amino acids at positions 15, 50, 58, 97, and combinations thereof in the amino acid sequence of SEQ ID NO: 20 is substituted with another amino acid. The first core domain may consist of the amino acid sequence of SEQ ID NO: 2.
Specifically, the core domain may include any one variation selected from the group consisting of the following variations (1) to (6):
(1) a variation in which arginine (R), which is the amino acid at position 15 in the amino acid sequence of SEQ ID NO: 20, is substituted with asparagine (N);
(2) a variation in which asparagine (N), which is the amino acid at position 50 in the amino acid sequence of SEQ ID NO: 20, is substituted with leucine (L);
(3) a variation in which serine (S), which is the amino acid at position 58 in the amino acid sequence of SEQ ID NO: 20, is substituted with lysine (K), arginine (R), asparagine (N), aspartic acid (D), glutamic acid (E), cysteine (C), or leucine (L);
(4) a variation in which aspartic acid (D), which is the amino acid at position 97 in the amino acid sequence of SEQ ID NO: 20, is substituted with leucine (L);
(5) a variation in which asparagine (N), which is the amino acid at position 50 in the amino acid sequence of SEQ ID NO: 20, and aspartic acid (D), which is the amino acid at position 97 in the amino acid sequence of SEQ ID NO: 20, are each substituted with cysteine (C) or serine (S); and
(6) a variation in which arginine (R), which is the amino acid at position 15 in the amino acid sequence of SEQ ID NO: 20, is substituted with asparagine (N), and serine (S), which is the amino acid at position 58 in the amino acid sequence of SEQ ID NO: 20, is substituted with lysine (K) or arginine (R).
Here, the core domain may consist of any one amino acid sequence selected from SEQ ID NOs: 6 to 19.
The N-terminal extension domain is a domain bound to the N-terminus of the above-described core domain, and may be a polypeptide consisting of any one amino acid sequence of SEQ ID NOs: 3 to 5.
As used herein, the expression “ΔN2” may also be indicated as “delta N2”, meaning that in the amino acid sequence of human GDF15 represented by SEQ ID NO: 1, the amino acids at positions 1 and 2 are deleted. In a case where ΔN2 is expressed as an N-terminal extension domain, it may be expressed as “NGDH” (SEQ ID NO: 112).
As used herein, the expression “ΔN3, WS insertion, G4N, D5S, H6T” may also be indicated as “delta N3, WS insertion, G4N, D5S, H6T”, meaning that in the amino acid sequence of human GDF15 represented by SEQ ID NO: 1, the amino acids at positions 1 to 3 are deleted, and tryptophan and serine are inserted therein; glycine, which is the amino acid at position 4, is substituted with asparagine; aspartic acid, which is the amino acid at position 5, is substituted with serine; and histidine, which is the amino acid at position 6, is substituted with threonine. In a case where the ΔN3, WS insertion, G4N, D5S, H6T is expressed as an N-terminal extension domain, it may be indicated as “WSNST” (SEQ ID NO: 113).
As used herein, the expression “ΔN3, G4N, D5S, H6T” may also be indicated as “delta N3, G4N, D5S, H6T”, meaning that in the amino acid sequence of human GDF15 represented by SEQ ID NO: 1, the amino acids at positions 1 to 3 are deleted; glycine, which is the amino acid at position 4, is substituted with asparagine; aspartic acid, which is the amino acid at position 5, is substituted with serine; and histidine, which is the amino acid at position 6, is substituted with threonine. In a case where the “ΔN3, G4N, D5S, H6T” is expressed as an N-terminal extension domain, it may be expressed as “NST.”
The GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a core domain consisting of any one amino acid sequence selected from SEQ ID NOs: 6 to 20. In addition, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 4 and a core domain consisting of any one amino acid sequence selected from SEQ ID NOs: 6 to 20. Furthermore, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 5 and a core domain consisting of any one amino acid sequence selected from SEQ ID NO: 6 to 19.
Preferably, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 3 and a core domain consisting of an amino acid sequence represented by SEQ ID NO: 8, 9, or 20. In addition, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 4 and a core domain consisting of an amino acid sequence represented by SEQ ID NO: 8, 9, or 20. Furthermore, the GDF15 variant may include an N-terminal extension domain consisting of an amino acid sequence represented by SEQ ID NO: 5 and a core domain consisting of any one amino acid sequence selected from SEQ ID NOs: 6, 7, and 10 to 19. Here, the GDF15 variant may consist of any one amino acid sequence selected from SEQ ID NOs: 21 to 39.
Long-Acting GDF15 Fusion Protein
In another aspect of the present invention, there is provided a long-acting GDF15 fusion protein, in which the GDF15 variant is bound to human IgG Fc or a variant thereof.
The human IgG Fc or a variant thereof may be Fc of IgG1, IgG2, IgG3, or IgG4, or a variant thereof. Specifically, the human IgG Fc or a variant thereof may be human IgG1 Fc or a variant thereof, and the human IgG1 Fc may consist of an amino acid sequence represented by SEQ ID NO: 41.
The human IgG Fc or a variant thereof may be a contiguous amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41, or a fragment of the Fc including a CH3 domain. In certain embodiments, the human IgG Fc or a variant thereof may be a contiguous amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41, or a fragment of the Fc including a CH2 domain and a CH3 domain. In certain embodiments, the human IgG Fc or a variant thereof may be a contiguous amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41, or a fragment of the Fc including a partial hinge region, a CH2 domain, and a CH3 domain. In certain embodiments, the human IgG Fc or a variant thereof may have an amino acid sequence that is 90%, 92%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 41.
The IgG Fc or a variant thereof includes a first polypeptide including an IgG1 Fc sequence, the IgG Fc sequence including a CH3 sequence that includes at least one engineered protuberance; and a second polypeptide including an IgG1 Fc sequence, the IgG Fc sequence including a CH3 sequence that includes at least one engineered cavity, in which the first polypeptide dimerizes with the second polypeptide via positioning of the protuberance of the first polypeptide into the cavity of the second polypeptide.
Specifically, the first polypeptide may include an engineered protuberance that allows binding to another IgG Fc polypeptide (for example, second polypeptide) including an engineered cavity. The second polypeptide may include an engineered cavity that allows binding to another IgG Fc polypeptide (for example, first polypeptide) including an engineered protuberance. In addition, the protuberance of the first polypeptide and the cavity of the second polypeptide may be each engineered into a CH3 domain of IgG Fc. Here, the protuberance of the first polypeptide and the cavity of the second polypeptide are neither connected nor bound to the GDF15 variant.
The engineered protuberance may include at least one substitution in the amino acid sequence of human IgG1 Fc having an amino acid sequence represented by SEQ ID NO: 41. Here, the amino acid positions are numbered according to EU numbering. The substitution may be present at a position selected from the group consisting of amino acid residues 347, 366, and 394. For example, the substitution may be any one selected from the group consisting of Q347W/Y, T366W/Y, T394W/Y, and combinations thereof. In addition, the engineered cavity may include at least one substitution in corresponding amino acids in the human IgG1 Fc sequence, and the substitution may be present at a position selected from the group consisting of amino acid residues 366, 368, 394, 405, and 407. For example, the substitution may be any one selected from the group consisting of T366S, L368A, T394S, F405T/V/A, Y407T/V/A, and combinations thereof.
Preferably, the protuberance may include the substitution T366W/Y, and the cavity may include any one substitution selected from the group consisting of T366S, L368A, Y407T/V/A, and combinations thereof. For example, the protuberance may include the substitution T366W/Y, and the cavity may include the substitution Y407T/V/A. In addition, the protuberance may include the substitution T366Y, and the cavity may include the substitution Y407T. In addition, the protuberance may include the substitution T366W, and the cavity may include the substitution Y407A. In addition, the protuberance may include the substitution T394Y, and the cavity may include the substitution Y407T.
The first polypeptide may consist of any one amino acid sequence selected from SEQ ID NOs: 42, 44, and 46, and the second polypeptide may consist of any one amino acid sequence selected from SEQ ID NOs: 43, 45, and 47.
The protuberance is referred to as “knob” and the cavity is referred to as “hole”.
The first polypeptide is Fc ‘knob’ including an engineered protuberance, and the second polypeptide is Fc ‘hole’ including an engineered protuberance. The first and second polypeptides may be physically associated with each other via non-covalent interactions (for example, hydrophobic effects, such as hydrophobic interaction between the knob and hole regions of the Fc), covalent bonds (for example, disulfide bonds such as one or two or more disulfide bonds between hinge regions of the Fc in the first and second polypeptides), or both.
As used herein, the term “dimer” refers to a protein complex including at least two polypeptides. Each of these polypeptides includes an N-terminus and a C-terminus. At least two polypeptides may be associated with each other via one or both of covalent and non-covalent (for example, electrostatic, π-effects, van der Waals forces, and hydrophobic effects) interactions. The two polypeptides may have the same amino acid sequence or may be different from each other. In a case where the two polypeptides are identical to each other, the dimer is referred to as a (homo)dimer; and in a case where the two polypeptides are different from each other, the dimer is referred to as a heterodimer.
The human IgG Fc or a variant thereof may be a heterodimer including a first polypeptide and a second polypeptide; and the heterodimer may be a heterodimer formed of A-1 (SEQ ID NO: 42) and A-2 (SEQ ID NO: 43), a heterodimer formed of B-1 (SEQ ID NO: 44) and B-2 (SEQ ID NO: 45), or a heterodimer formed of C-1 (SEQ ID NO: 46) and C-2 (SEQ ID NO: 47).
In addition, the IgG Fc or a variant thereof may include an additional mutation, to improve properties of a long-acting GDF15 fusion protein. Specifically, a heterodimer consisting of the first polypeptide and the second polypeptide may include an additional mutation.
For example, the IgG Fc or a variant thereof may include mutation(s) that abolish (for example, decrease or eliminate) IgG effector function. Specifically, an Fc partner sequence may include mutation(s) that abolish effector functions such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). For example, the mutations E233A and L235A may be introduced into the IgG Fc formed of A-1 and A-2 or a variant thereof (which is a heterodimer), to eliminate IgG1 effector function. The heterodimer formed of B-1 and B-2, which includes the mutation N297A, can be used to eliminate N-linked glycans. Into the heterodimer formed of C-1 and C-2 may be introduced the mutations L234A, L235A, and N297A, to eliminate IgG1 effector function and N-linked glycans.
Binding between the GDF15 variant and the IgG Fc or a variant thereof may be such that the C-terminus of the first polypeptide or the C-terminus of the second polypeptide, in the IgG Fc or a variant thereof, is bound to the N-terminus of the GDF15 variant. In addition, binding between the GDF15 variant and the IgG Fc or a variant thereof may be such that the N-terminus of the first polypeptide or the N-terminus of the second polypeptide, in the IgG Fc or a variant thereof, is bound to the C-terminus of the GDF15 variant. Preferably, binding between the GDF15 variant and the IgG Fc or a variant thereof may be such that the C-terminus of the first polypeptide in the IgG Fc or a variant thereof is bound to the N-terminus of the GDF15 variant.
In addition, binding between the GDF15 variant and the IgG Fc or a variant thereof may be made through a linker. The linker may be a peptide that consists of 10 to 50 amino acid residues, including glycine, serine, alanine, and glutamic acid residues. The linker may include (G4S)n, where n may be an integer of 1 to 10 or an integer of 2 to 7. For example, n may be 2, 3, 4, 5, 6, or 7. In an embodiment of the present invention, a linker including (G4S)5, which is a case where n is an integer of 5, was used.
As an example of a suitable linker other than the linker including (G4S)n (SEQ ID NO: 48), a linker including GS(G4S)n (SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94), GS(EEEA)n (SEQ ID NO: 95), (EEEA)n (SEQ ID NO: 110), GS(EAAAK)n (SEQ ID NO: 97), (EAAAK)n (SEQ ID NO: 111), or GSGGSS(PT)n (SEQ ID NO: 96) may be mentioned, where n may be an integer of 1 to 10. However, the suitable linker is not limited thereto. In an embodiment of the present invention, a linker including GS(EEEA)6, which is a case where n is an integer of 6, or a linker including GS(EAAAK)5, which is a case where n is an integer of 5, was used.
The long-acting GDF15 fusion protein includes one GDF15 variant per heterodimer consisting of a first polypeptide and a second polypeptide. The GDF15 variant may include at least one N-linked glycan.
The long-acting GDF15 fusion protein may include i) a GDF15 variant consisting of any one amino acid sequence selected from SEQ ID NOs: 21 to 39, ii) a first polypeptide consisting of any one amino acid sequence selected from SEQ ID NOs: 42, 44, and 46, and iii) a second polypeptide consisting of any one amino acid sequence selected from SEQ ID NOs: 43, 45, and 47.
Preferably, the long-acting GDF15 fusion protein may include i) a GDF15 variant consisting of any one amino acid sequence selected from SEQ ID NOs: 21 to 39, ii) a linker consisting of the amino acid sequence of SEQ ID NO: 48, iii) a first polypeptide consisting of the amino acid sequence of SEQ ID NO: 42, and iv) a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 43.
Still preferably, the long-acting GDF15 fusion protein may include i) a GDF15 variant consisting of any one amino acid sequence selected from SEQ ID NOs: 21 to 39, ii) a linker consisting of any one amino acid sequence selected from SEQ ID NOs: 92 to 97, iii) a first polypeptide consisting of the amino acid sequence of SEQ ID NO: 46, and iv) a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 47.
Fusion Protein Dimer
In still yet another aspect of the present invention, there is provided a fusion protein dimer, comprising two of the long-acting GDF15 fusion protein. Specifically, the two long-acting GDF15 fusion proteins are dimerized through GDF15-GDF15 interaction, and this was designated “fusion protein dimer”.
Nucleic Acid Molecule, Expression Vector, and Host Cell
In still yet another aspect of the present invention, there is provided an isolated nucleic acid molecule, encoding the GDF15 variant or the long-acting GDF15 fusion protein.
As used herein, the term “isolated nucleic acid molecule” refers to a nucleic acid molecule of the present invention that has been separated from at least about 50% of proteins, lipids, carbohydrates, or other materials with which it is naturally found when the entire nucleic acid is isolated from source cells; is operably linked to a polynucleotide which it is not linked to in nature; or does not occur in nature as part of a larger polynucleotide sequence. Specifically, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating nucleic acid molecules, or other contaminants that are found in its natural environment and would interfere with its use in polypeptide production, or its therapeutic, diagnostic, prophylactic, or research application.
Here, the isolated nucleic acid molecule that encodes the GDF15 variant or the long-acting GDF15 fusion protein may have different sequences due to codon redundancy. In addition, the isolated nucleic acid molecule may be appropriately modified or may have a nucleotide added to the N-terminus or C-terminus, depending on purposes, as long as it can produce the GDF15 variant or the long-acting GDF15 fusion protein.
In still yet another aspect of the present invention, there is provided an expression vector, comprising the isolated nucleic acid molecule that encodes the GDF15 variant or the long-acting GDF15 fusion protein.
As used herein, the term “expression vector” refers to a vector which is suitable for transformation of a host cell and contains a nucleic acid sequence that directs or controls expression of an inserted heterologous nucleic acid sequence. The vector includes linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors, and analogs thereof. Examples of the viral vector include, but are not limited to, a retrovirus, an adenovirus, and an adeno-associated virus.
As used herein, the term “expression of a heterologous nucleic acid sequence” or “expression” of a target protein refers to transcription of an inserted DNA sequence, translation of an mRNA transcript, and production of a fusion protein product, an antibody, or an antibody fragment.
A useful expression vector may be RcCMV (Invitrogen, Carlsbad) or a variant thereof. The useful expression vector may include a human cytomegalovirus (CMV) promoter for promoting continuous transcription of a target gene in mammalian cells, and a bovine growth hormone polyadenylation signal sequence for increasing a post-transcriptional RNA stability level.
In still yet another aspect of the present invention, there is provided a host cell, comprising the expression vector.
As used herein, the term “host cell” refers to a prokaryotic or eukaryotic cell into which a recombinant expression vector can be introduced. As used herein, the term “transformed” or “transfected” means that a nucleic acid (for example, vector) is introduced into a cell by a number of techniques known in the art.
The host cell may be transformed or transfected with a DNA sequence of the present invention, and may be used for expression and/or secretion of a target protein. Examples of the host cell that can be used in the present invention may include immortal hybridoma cells, NS/0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, CAP cells (human amniotic fluid-derived cells), and COS cells.
Pharmaceutical Composition
In a still yet another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer.
The pharmaceutical composition of the present invention can be administered via any route. The composition of the present invention may be provided to an animal either directly (for example, topically, by injection, implantation, or local administration to a tissue site) or systemically (for example, by parenteral or oral administration) using any appropriate means. In a case where the composition of the present invention is parenterally provided, such as by intravenous, subcutaneous, ophthalmic, intraperitoneal, intramuscular, rectal, intraorbital, intracerebral, intracranial, intraspinal, intraventricular, intrathecal, intracisternal, intracapsular, intranasal, or aerosol administration, the composition may be aqueous or include a portion of a physiologically applicable body fluid suspension or solution. Accordingly, since a carrier or vehicle is physiologically acceptable, it may be added to the composition and delivered to a patient. Therefore, physiological saline may be generally included as a body fluid-like carrier for formulations.
In addition, frequency of administration may vary depending on pharmacokinetic parameters of the GDF15 variant in a formulation used. Typically, physicians would administer the pharmaceutical composition until the dose thereof reaches a dose that achieves a desired effect. Thus, the pharmaceutical composition may be administered as a single dose, or two or more doses at time intervals (which may or may not contain an equal amount of a target fusion protein), or may be administered as continuous infusion through an implantable device or catheter. Further refinement of an appropriate dose is routinely made by those skilled in the art and falls within the scope of work which is routinely performed by them.
In addition, a unit dose of the fusion protein in humans is 0.01 μg to 100 mg/kg body weight, and specifically, 1 μg to 10 mg/kg body weight. Although the above-mentioned amount is an optimal amount, the amount may vary depending on a disease to be treated, or presence or absence of adverse effects. An optimal dose may be determined using a conventional experiment. Administration of the fusion protein may be made by periodic bolus injections, or continuous intravenous, subcutaneous, or intraperitoneal administration from an external reservoir (for example, intravenous bag) or an internal reservoir (for example, biodegradable implant).
In addition, the fusion protein of the present invention may be administered to a subject recipient together with other biologically active molecules. However, an optimal combination of the fusion protein and other molecules, and dosage forms and precise doses thereof may be determined by conventional experiments well known in the art.
In still yet another aspect of the present invention, there is provided a use of the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, for prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome.
In still yet another aspect of the present invention, there is provided a use of the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer, for manufacture of a medicament for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome.
In still yet another aspect of the present invention, there is provided a method for preventing or treating diabetes, obesity, dyslipidemia, or metabolic syndrome, comprising a step of administering, to an individual, the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer.
Dose, frequency of administration, and route of administration of the GDF15 variant, the long-acting GDF15 fusion protein, or the fusion protein dimer are the same as described above. The individual may be an individual suffering from diabetes, obesity, dyslipidemia, or metabolic syndrome. In addition, the individual may be a mammal, preferably a human.
Hereinafter, for better understanding of the present invention, the present invention will be described in detail by way of examples. However, the examples according to the present invention may be modified in a variety of different forms, and the scope of the present invention should not be construed as being limited to the following examples.
In general, in a case where a substance is fused to long-acting Fc or albumin to increase its half-life, the fusion results in a decrease in activity of the substance. To improve this, various GDF15 variants were designed.
First, first polypeptides were prepared by performing substitutions of respective amino acids at positions 32, 51, 56, 60, 64, 90, 92, 93, 97, 101, and 103 in GDF15, which are predicted to have a large effect on protein activity through three-dimensional structure analysis of GDF15, and causing the resulting GDF15's to be bound to IgG1 Fc_knob, and these first polypeptides are shown in Table 1 below.
Specifically, to produce a first polypeptide (FM series) having a structure of Fc_knob-(G4S)5-GDF15 variant and a second polypeptide having Fc_hole structure, gene cloning was conducted using pcDNA3.3 (Invitrogen) expression vector that includes a gene encoding a first polypeptide consisting of any one amino acid sequence of SEQ ID NOs: 49, 60, 65, and 69 to 90 and a gene encoding a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 43. Here, nucleotide sequences encoding the amino acid sequences of SEQ ID NOs: 43, 49, 60, 65, and 69 to 90 were synthesized by making a request to Macrogen, Inc.
The pcDNA3.3 expression vector cloned in Example 1.1 was transiently transfected into ExpiCHO cell line (Invitrogen). Then, on Day 8, the cell culture was harvested and purified. To purify the first polypeptide and the second polypeptide in the harvest cell culture fluid (HCCF), affinity purification using Protein A resin was performed.
Specifically, the HCCF was loaded onto MabSelect SuRe Protein A resin (GE Healthcare) equilibrated with 1×PBS (pH 7.4), to induce binding. After completion of the binding between the first polypeptide and the second polypeptide, the MabSelect SuRe Protein A resin was washed with 1×PBS (pH 7.4). Then, elution was performed using 0.1 M glycine (pH 3.0) solution, to obtain a final substance.
The first polypeptide and the second polypeptide were neutralized to a level of about pH 8.0 using 1 M Tris-HCl solution. The first polypeptide and the second polypeptide were completely dimerized through knob-in-hole interaction, and this was designated “long-acting GDF15 fusion protein”. Two molecules of the long-acting GDF15 fusion protein were dimerized again through GDF15-GDF15 interaction, and this was designated “fusion protein dimer”.
Using a fusion protein that includes mature GDF15 consisting of the amino acid sequence of SEQ ID NO: 49, as a control, the long-acting GDF15 fusion proteins produced in Example 1 were compared in terms of GDF15 activity. The GDF15 activity was measured using a BRIGHT-GLO′ luciferase assay kit (Promega) and human embryonic kidney 293 (HEK293) cell line overexpressing GFRAL/RET/SRE-luc.
Specifically, 1×105 HEK293 cells overexpressing GFRAL/RET/SRE-luc were dispensed into each well of a 96-well-plate in DMEM medium containing 10% FBS, and then incubated for 24 hours at 37° C. and 5% CO2. After 24 hours, each medium in the 96-well-plate was replaced with 50 μl of serum-free medium, and incubated for 4 hours at 37° C. and 5% CO2.
In addition, each of the long-acting GDF15 fusion proteins produced in Example 1 was prepared by 3-fold serial dilution starting from a concentration of 2000 nM using serum-free medium. Then, 50 μl of the long-acting GDF15 fusion protein dilution was added to each well that contains 50 μl of the replaced serum-free medium and the GFRAL/RET/SRE-luc cell line, so that the actual concentration was obtained by 3-fold serial dilution starting from 1000 nM. Then, reaction was allowed to proceed for 4 hours at 37° C. and 5% CO2. After 4 hours, each well was treated with 100 μl of BRIGHT-GLO™ solution, which had been prepared by adding BRIGHT-GLO™ buffer to BRIGHT-GLO™ substrate, and reaction was allowed to proceed for 1 minute at room temperature.
Thereafter, relative light unit (RLU) values were measured with a microplate reader (Perkin Elmer, Wallac Victor X5) capable of measuring luminescence. The results are shown in Table 2 below. Here, two improved long-acting GDF15 fusion proteins were selected based on in vitro GDF15 activity (Emax of 100%) of the fusion protein (FWT+Fc_hole) including mature GDF15, which was a control.
As a result, the two selected long-acting GDF15 fusion proteins were a long-acting GDF15 fusion protein (hereinafter referred to as FM4+Fc_hole) having the mutations ΔN2, N56C, and D103C, and a long-acting GDF15 fusion protein (hereinafter referred to as FM5+Fc_hole) having the mutations ΔN2 and S64K; and their in vitro GDF15 activity (Emax) was measured to be 133.3% and 147.2%, respectively. From these results, it was identified that the FM4+Fc_hole and the FM5+Fc_hole had improved in vitro GDF15 activity.
In GDF15-GDF15 interaction between the long-acting GDF15 fusion proteins, it was identified in Example 2 that the FM4+Fc_hole, to which an additional disulfide bond was introduced, had improved in vitro GDF15 activity. On the basis of these results, to identify importance of the disulfide bond, long-acting GDF15 fusion proteins, which were based on the FM4+Fc_hole and in which asparagine (N), which is the amino acid at position 56 in mature GDF15, and/or aspartic acid (D), which is the amino acid at position 103 in mature GDF15, was substituted with another amino acid, were additionally designed as shown in Table 3 below, and produced in the same manner as in Example 1. Then, in vitro GDF15 activity was evaluated in the same manner as in Example 2.
As a result, as shown in Table 3, it was identified that only the FM4+Fc_hole improved in vitro GDF15 activity (Emax) as compared with the FWT+Fc_hole (
It was identified in Example 2 that the FM5+Fc_hole, which is an S64K variant of GDF15, had improved in vitro GDF15 activity. On the basis of these results, long-acting GDF15 fusion proteins, which were based on the FM5+Fc_hole and in which serine (S), which is the amino acid at position 64 in mature GDF15 was substituted with another amino acid, were additionally designed as shown in Table 4 below, and produced in the same manner as in Example 1. Then, in vitro GDF15 activity was evaluated in the same manner as in Example 2.
As a result, as shown in Table 4, it was identified that only the FM9+Fc_hole had improved in vitro GDF15 activity (Emax) as compared with FWT (
The FM4+Fc_hole, the FM5+Fc_hole, and the FM9+Fc_hole, having improved in vitro GDF15 activity, in Examples 3 and 4 were compared in terms of binding affinity for GFRAL and RET which are GDF15 receptors. To measure binding affinity for the GDF15 receptors, a cell-based enzyme-linked immunosorbent assay (ELISA) was performed using the HEK293 cell line overexpressing GFRAL and RET.
Specifically, 1×105 HEK293 cells overexpressing GFRAL/RET/SRE-luc were dispensed into each well of a 96-well-plate in DMEM medium containing 10% FBS, and then incubated for 24 hours at 37° C. and 5% CO2. After 24 hours, the medium was removed from each well of the 96-well-plate. Then, each medium was treated with 4% paraformaldehyde and reaction was allowed to proceed for 20 minutes at room temperature. Paraformaldehyde was removed therefrom. Treatment with 0.6% hydrogen peroxide solution was performed, and reaction was allowed to proceed again for 20 minutes. Then, treatment with 3% bovine serum albumin (BSA)-phosphate buffered saline with Tween 20 (PBST) buffer was performed, and blocking was allowed to proceed for 2 hours.
In addition, the FM4+Fc_hole, the FM5+Fc_hole, or the FM9+Fc_hole was subjected to 2-fold serial dilution, starting from 200 μg/mL, using PBS buffer containing 1% BSA. 100 μl of the FM4+Fc_hole, the FM5+Fc_hole, or the FM9+Fc_hole, each of which was diluted in various concentrations, was applied to a 96-well-plate containing a GFRAL/RET-overexpressing cell line, and reaction was allowed to proceed for 2 hours at room temperature. Then, each well was treated with horseradish peroxidase (HRP)-conjugated anti-human IgG-Fc antibody (Jackson ImmunoResearch #109-035-098), and then developed with 3,3,5,5-tetramethylbenzidine (TMB) buffer (Bio-Rad #172-1066).
Each well was treated with 100 μl of TMB solution, and reaction was allowed to proceed for 10 minutes at room temperature. Then, the reaction was stopped using a 2N sulfuric acid (H2SO4) reagent. Then, absorbance was measured at 450 nm with a microplate reader (Perkin Elmer, Wallac Victor X5) to evaluate binding capacity, to the GDF15 receptors, of the GDF15 variant in the long-acting GDF15 fusion protein (dimer).
As a result, as illustrated in
To improve purification yield, purity, and the like of each long-acting GDF15 fusion protein at the time of producing the same, N-linked glycans were introduced at various positions in GDF15. Presence of N-linked glycans in the GDF15 sequence is known to increase retention time of the corresponding protein in the endoplasmic reticulum and Golgi apparatus during a process of protein secretion, thereby minimizing misfolded products and helping protein expression. Increased retention time has a beneficial effect on folding kinetics and can result in significantly improved heterodimeric (Fc/Fc) knob-in-hole assembly and recovery from mammalian tissue culture.
Evaluation of purity improvement after purification for a substance, obtained by introducing N-linked glycans into a long-acting GDF15 fusion protein, as compared with a dimer of the fusion protein FWT+Fc_hole as a control, was performed in terms of correctly-assembled fusion protein dimer purity using size-exclusion chromatography analysis.
Specifically, long-acting GDF15 fusion proteins, in which N-linked glycans were introduced at various positions in GDF15, were additionally designed. In this regard, variants having increased correctly-assembled fusion protein dimer purity, which was obtained in a case where the variants were produced and subjected to first-step purification in the same manner as in Example 1, as compared with a dimer of the fusion protein FWT+Fc_hole, are shown in Table 6.
As a result, it was identified that the FWT+Fc_hole had correctly-assembled fusion protein dimer purity after first-step purification of 50.9%, whereas the FM1+Fc_hole, the FM2+Fc_hole, the FM3+Fc_hole, the FM10+Fc_hole, the FM11+Fc_hole, and the FM12+Fc_hole, in each of which N-linked glycans were introduced into GDF15, had improved, correctly-assembled fusion protein dimer purity of 80.2%, 73.0%, 86.3%, 65.2%, and 70.3%, respectively.
In addition, the NGM Biopharmaceuticals, Inc.'s fusion protein dimer (B13a/B13b (into which N-linked glycans are introduced) in U.S. Pat. No. 9,920,118 was measured to have purity of 75.8%.
Using the FM1+Fc_hole, the FM2+Fc_hole, and the FM3+Fc_hole, in each of which N-linked glycans were introduced at various positions in GDF15, as controls, the FM10+Fc_hole, the FM11+Fc_hole, and the FM12+Fc_hole were evaluated, in terms of GDF15 activity, in the same manner as in Example 2. The results are shown in Table 7.
As a result, as shown in Table 7, it was identified that the FM10+Fc_hole, the FM11+Fc_hole, and the FM12+Fc_hole had improved GDF15 activity (Emax) as compared with the FM1+Fc_hole, the FM2+Fc_hole, and the FM3+Fc_hole (
Binding affinity of the FM10+Fc_hole or the FM11+Fc_hole for the GDF15 receptors, GFRAL and RET, were compared and evaluated in the same manner as in Example 5. As a result, as illustrated in
Based on the results of Examples 1 to 8, long-acting GDF15 fusion proteins, in which the amino acids at positions 21 and/or 64 were substituted and N-linked glycans were introduced at various positions in GDF15, were additionally designed. In this regard, variants having increased correctly-assembled fusion protein dimer purity, which was obtained in a case where the variants were produced and subjected to first-step purification in the same manner as in Example 1, as compared with a dimer of the fusion protein FWT+Fc_hole, are shown in Table 8.
In order to conduct optimization studies of a fusion carrier and a linker for the two variants (FM9+Fc_hole and FM11+Fc_hole) showing excellent activity and purity improvement after purification, long-acting GDF15 fusion proteins, in which fusion carriers (SEQ ID NOs: 46 and 47) and various linkers (SEQ ID NOs: 92, 93, 94, 95, 96, and 97) were introduced into respective GDF15 sequences to minimize an effector function, were additionally designed and are shown in Table 9.
The optimized long-acting GDF15 fusion proteins as shown in Table 9 were produced and subjected to first-step purification in the same manner as in Example 1. To obtain a high-purity long-acting GDF15 fusion protein, a pool obtained by completing the first-step purification was subjected to second-step ion exchange (IEX) purification using anion exchange (AEX) resin and cation exchange (CEX) resin.
Specifically, for the anion exchange (AEX), the pool that had undergone the first step was loaded onto POROS HQ™ 50 μM Strong Anion Exchange Resin (Thermo Fisher Scientific) equilibrated with 1×PBS (pH 7.4), to induce binding. After completion of the binding between the first polypeptide and the second polypeptide, the POROS HQ™ 50 μM Strong Anion Exchange Resin was washed with 1×PBS (pH 7.4), and then elution was performed by concentration gradient using 50 mM Tris-HCl (pH 8.0) solution with 1 M sodium chloride, to obtain a final substance. Fractions meeting a criterion for purity of 95% or higher were pooled using size exclusion chromatography analysis.
In addition, for the cation exchange (CEX), the pool that had undergone the first step was subjected to pH adjustment depending on isoelectric points, and then loaded onto POROS XS™ Strong Cation Exchange Resin (Thermo Fisher Scientific) equilibrated with 20 mM sodium phosphate (pH 6.5) solution, to induce binding. After completion of the binding between the first polypeptide and the second polypeptide, the POROS XS™ Strong Cation Exchange Resin was washed with 20 mM sodium phosphate (pH 6.5) solution, and then elution was performed by concentration gradient using 20 mM sodium phosphate (pH 6.5) solution with 1 M sodium chloride, to obtain a final substance. Fractions meeting a criterion for purity of 95% or higher were pooled using size exclusion chromatography analysis.
The two variants (FM9+Fc_hole and FM11+Fc_hole) showing excellent activity and purity improvement after purification were compared and evaluated in terms of activity depending on linker type and length. Activity of the respective long-acting GDF15 fusion proteins was evaluated in the same manner as in Example 2, and the results are shown in Table 10. Here, the long-acting GDF15 fusion proteins were compared, in terms of activity depending on GDF15 sequence, and linker type and length, based on in vitro GDF15 activity (Emax of 100%) of the FM9-6+Fc_hole.
As a result, as shown in Table 10, it was identified that the respective long-acting GDF15 fusion proteins exhibited similar activity except those in which the linker GS(EEEA)6 (SEQ ID NO: 95) was used, and the long-acting GDF15 fusion proteins (FM9-4+Fc_hole and FM11-4+Fc_hole), in which linker GS(EEEA)6 (SEQ ID NO: 95) was used, exhibited relatively low EC50 value and high Emax value (
On the day of drug treatment, six-week-old male C57BL/6 mice purchased from Orient BIO (Korea) were divided into groups (n=3 per blood collection time point) so that each group had a similar average value of body weight, and then the FM9-4+Fc_hole, the FM9-6+Fc_hole, the FM11-4+Fc_hole, and the FM11-6+Fc_hole were respectively administered subcutaneously once at a dose of 1 mg/kg. Blood samples were respectively collected 4, 24, 48, 72, 96, 120, 168, and 240 hours after the administration. A concentration of each long-acting GDF15 fusion protein (dimer) in mouse blood was measured using an immunoassay method. Based on the measured concentration values, pharmacokinetic parameter results were calculated for the respective long-acting GDF15 fusion proteins (dimers) and are shown in Table 11 below.
Diet-induced obese (DIO) mice which have been induced by feeding a high-fat diet in mice, and are characterized by obesity, hyperglycemia, and insulin resistance. The DIO mice (Taconic, USA) which had been fed a high fat diet (60 kcal % fat, Research Diets, Cat #D12492, USA) in C57BL/6N mice for 8 weeks were purchased from Raon Bio (Animal Inc., Republic of Korea). After the arrival, these animals were additionally fed by the high-fat diet (60% fat) for 5 weeks, and then used in this study. On the day before the dosing start, the animals were divided into groups (n=6 per group) based on mean body weight of individual mice, and then FM9-4+Fc_hole, FM9-6+Fc_hole, FM11-4+Fc_hole, and FM11-6+Fc_hole were administered subcutaneously at 2-day interval (Q2D) for a total of 4 weeks at a dose of 10 nmol/kg, respectively. As reference articles, B13a/B13b (U.S. Pat. No. 9,920,118) at 10 nmol/kg and semaglutide at 30 nmol/kg were administered subcutaneously at 2-day interval (Q2D) for a total of 4 weeks. For vehicle treatment, Dulbecco's phosphate buffered saline (DPBS; Gibco, USA) was administered subcutaneously at 2-day interval (Q2D). Body weight was measured every two days from the first day of drug treatment to Day 28, and the results were shown in Table 12 below.
As a result, it was confirmed that all test articles with different linker types (FM9-4+Fc_hole, FM9-6+Fc_hole, FM11-4+Fc_hole, and FM11-6+Fc_hole) demonstrated a marked body weight loss effect, compared to B13a/B13b of 10 nmol/kg, as a reference drug. In addition, three test articles, FM9-4+Fc_hole, FM9-6+Fc_hole, and FM11-4+Fc_hole, showed a body weight reduction effect similar to semaglutide, 30 nmol/kg-treated group (
Male C57BL/6N mice at 6-week-old were purchased from Orient Bio (via Hallym Lab. Animal Inc., Republic of Korea). After the arrival, C57BL/6N mice were induced DIO by feeding with a high-fat diet (60 kcal % fat, Research Diets, Cat #D12492, USA) for a total of 13 weeks. On the day before the dosing start, the animals were divided into groups (n=6 per group) based on mean body weight of individual mice, and then FM9-6+Fc_hole of 1, 3, 10, and 30 nmol/kg was administered subcutaneously once. As a reference article, semaglutide of 30 nmol/kg was administered subcutaneously once. For vehicle treatment, Dulbecco's phosphate buffered saline (DPBS; Gibco, USA) was administered subcutaneously. A body weight was measured daily from the day of drug treatment to Day 42, and the results are shown in Table 13 below.
As a result, in terms of body weight loss effect by single administration, the semaglutide, 30 nmol/kg treated group, as a reference article, demonstrated a pharmacologic effect lasting for 2 days, whereas the single administration of FM9-6+Fc_hole of 1, 3, 10, and 30 nmol/kg was confirmed that anti-obesity effect lasted for 10 days, 15 days, 18 days, and 18 days, respectively for each doses (
ob/ob mice are genetically deficient in leptin gene and are characterized by hyperglycemia, insulin resistance, hyperorexia, and obesity. Male ob/ob mice at 5-week-old (Jackson Laboratory, USA) were purchased from Raon Bio (Animal Inc., Republic of Korea). The mice were acclimatized for 4 weeks with normal chow diet (Teklad Certified Irradiated Global 18% Protein Rodent Diet, 2918C, Harlan Co., USA) and drug treatment was initiated at 9-week-old. On the day before the dosing start, the animals were divided into groups (n=6 per group) based on mean body weight and random blood glucose via tail vein of individual mice. Then, the FM9-6+Fc_hole of 0.1, 1, and 3 nmol/kg, and semaglutide of 10 nmol/kg were administered subcutaneously at 3-day interval (Q3D) a total of 10 times, and body weight and food intake were measured every day or every 3 days during experimental period (Day 1- Day 29), respectively. For vehicle treatment, Dulbecco's phosphate buffered saline (DPBS; Gibco, USA) was administered.
As a result, it was confirmed that FM9-6+Fc_hole manifested body weight loss effect in a dose-dependent manner. FM9-6+Fc_hole, 0.1 nmol/kg treated group showed significant reduction in body weight similar to semaglutide, 10 nmol/kg treated group. FM9-6+Fc_hole of 1 nmol/kg or more demonstrated the maximal efficacy in ob/ob mice (
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2019-0153680 | Nov 2019 | KR | national |
This application is a national stage application of PCT/KR2020/016842 filed Nov. 25, 2020, which claims priority based on Korean Patent Application No. 10-2019-0153680 filed Nov. 25, 2019.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2020/016842 | 11/25/2020 | WO |
